Bayer AG seeks to acquire over-the-counter drugs from other drugmakers as part of a plan to balance its drug business, the firm's health care head says. Arthur Higgins said the firm hopes to "find attractive OTC assets," which he said was a reflection of an industry realization that drugmakers need a pipeline of specialist medicines.

Related Summaries